piv-3 Search Results


90
ViraTree LLC piv3-gfp virus p323
Piv3 Gfp Virus P323, supplied by ViraTree LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/piv-3/piv3+gfp+virus+p323/pmc07494516-39-0-7
Average 90 stars, based on 1 article reviews
piv3-gfp virus p323 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Promega interferon induction activity measuring reporter plasmid (piv3
Interferon Induction Activity Measuring Reporter Plasmid (Piv3, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/piv-3/interferon+induction+activity+measuring+reporter+plasmid++piv3/us09145564-277-6-40
Average 90 stars, based on 1 article reviews
interferon induction activity measuring reporter plasmid (piv3 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Glaxo Smith antibody titre against intramuscular poliovirus type 3
Equivalent schedules of intradermal fractional‐dose inactivated poliovirus vaccine compared to intramuscular inactivated poliovirus vaccine for the prevention of poliomyelitis in children
Antibody Titre Against Intramuscular Poliovirus Type 3, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/piv-3/live+attenuated+parainfluenza+virus+type+3++piv3++vaccine/pmc06923520-1109-2-21
Average 90 stars, based on 1 article reviews
antibody titre against intramuscular poliovirus type 3 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Boehringer Ingelheim bhv-1, bvdv, piv-3, brsv live vaccine; m. haemolytica bacterin
USDA licensed antiviral and antibacterial vaccines and preventative therapeutic products for cattle.
Bhv 1, Bvdv, Piv 3, Brsv Live Vaccine; M. Haemolytica Bacterin, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/piv-3/bhv+1++bvdv++piv+3++brsv+live+vaccine/pmc08276037-31-3-10
Average 90 stars, based on 1 article reviews
bhv-1, bvdv, piv-3, brsv live vaccine; m. haemolytica bacterin - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sanofi combined rsv, hmpv, piv3 mrna vaccine
Schematic representation of prefusion ( A <t>)</t> <t>RSV-F</t> (PDB ID: 8W3P) or ( B ) postfusion RSV-F (PDB ID: 3RRT); schematic representation of ( C ) prefusion <t>HMPV-F</t> PDB ID: 7SEJ) or ( D ) postfusion HMPV-F (PDB ID: 7m0i); genome organization of ( E ) HMPV or ( F ) RSV. Created with PyMOL and BioRender.
Combined Rsv, Hmpv, Piv3 Mrna Vaccine, supplied by Sanofi, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/piv-3/combined+rsv++hmpv++piv3+mrna+vaccine/pmc12197412-15-7-2
Average 90 stars, based on 1 article reviews
combined rsv, hmpv, piv3 mrna vaccine - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Argene Inc coronavirus (nl63, oc43, khu1, 229e) and parainfluenza (piv1, piv2, piv3, piv4) kit
Schematic representation of prefusion ( A <t>)</t> <t>RSV-F</t> (PDB ID: 8W3P) or ( B ) postfusion RSV-F (PDB ID: 3RRT); schematic representation of ( C ) prefusion <t>HMPV-F</t> PDB ID: 7SEJ) or ( D ) postfusion HMPV-F (PDB ID: 7m0i); genome organization of ( E ) HMPV or ( F ) RSV. Created with PyMOL and BioRender.
Coronavirus (Nl63, Oc43, Khu1, 229e) And Parainfluenza (Piv1, Piv2, Piv3, Piv4) Kit, supplied by Argene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/piv-3/coronavirus++nl63++oc43++khu1++229e++and+parainfluenza++piv1++piv2++piv3++piv4++kit/pmc07185839-50-15-15
Average 90 stars, based on 1 article reviews
coronavirus (nl63, oc43, khu1, 229e) and parainfluenza (piv1, piv2, piv3, piv4) kit - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
ViraTree LLC piv3–gfp
a – c , Calu-3 mucin GOF cells were infected with ( a ) SARS-CoV-2, ( b ) HKU5-SARS-CoV-S or ( c ) MERS-CoV at an MOI of 0.1. At 24 h postinfection, viral titers were quantified by plaque assay. The dotted line is the NTG average, n = 3 biological replicates. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. d , As a – c , except on WT Calu-3 cells pretreated with StcE. n = 3 biological replicates, two-sided t -tests were performed for the indicated pairs. e , Calu-3 cells were treated with StcE or left untreated and then infected with the indicated virus for 24 h. Relative levels of viral gene copies were quantified by RT–qPCR. Displayed are n = 4 (HCoV-229E), n = 10 (HCoV-OC43), n = 15 (Influenza A virus, PR8), n = 5 <t>(PIV3)</t> and n = 10 (RSV) biological replicates. Two-sided t -tests were performed for the indicated pairs. f , g . Mucin-overexpressing Calu-3 cells were infected with HCoV-229E or PIV3, and relative levels of viral gene copies were quantified 24 h postinfection by RT–qPCR. n = 3 biological replicates, the dotted line is the NTG average. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. h , PIV3 infection of the indicated GOF Calu-3 cells, with and without StcE treatment, at 48 h postinfection quantifying GFP + cells. Displayed is a single time point from the experiment shown in Extended Data Fig. . Displayed are n = 5 biological replicates, two-sided t -tests were performed for the indicated pairs. Dotted lines indicate the NTG average for two separate guides, with (upper) and without (lower) StcE treatment. Error bars denote mean ± s.e.m. NS, not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
Piv3–Gfp, supplied by ViraTree LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/piv-3/human+parainfluenza+virus+type+iii++piv3++strain+js/pmc09355872-313-2-22
Average 90 stars, based on 1 article reviews
piv3–gfp - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Biotechnology Information piv-3 sequence accession numbers
a – c , Calu-3 mucin GOF cells were infected with ( a ) SARS-CoV-2, ( b ) HKU5-SARS-CoV-S or ( c ) MERS-CoV at an MOI of 0.1. At 24 h postinfection, viral titers were quantified by plaque assay. The dotted line is the NTG average, n = 3 biological replicates. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. d , As a – c , except on WT Calu-3 cells pretreated with StcE. n = 3 biological replicates, two-sided t -tests were performed for the indicated pairs. e , Calu-3 cells were treated with StcE or left untreated and then infected with the indicated virus for 24 h. Relative levels of viral gene copies were quantified by RT–qPCR. Displayed are n = 4 (HCoV-229E), n = 10 (HCoV-OC43), n = 15 (Influenza A virus, PR8), n = 5 <t>(PIV3)</t> and n = 10 (RSV) biological replicates. Two-sided t -tests were performed for the indicated pairs. f , g . Mucin-overexpressing Calu-3 cells were infected with HCoV-229E or PIV3, and relative levels of viral gene copies were quantified 24 h postinfection by RT–qPCR. n = 3 biological replicates, the dotted line is the NTG average. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. h , PIV3 infection of the indicated GOF Calu-3 cells, with and without StcE treatment, at 48 h postinfection quantifying GFP + cells. Displayed is a single time point from the experiment shown in Extended Data Fig. . Displayed are n = 5 biological replicates, two-sided t -tests were performed for the indicated pairs. Dotted lines indicate the NTG average for two separate guides, with (upper) and without (lower) StcE treatment. Error bars denote mean ± s.e.m. NS, not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
Piv 3 Sequence Accession Numbers, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/piv-3/piv+3+sequence+accession+numbers/pmc11036794-67-4-13
Average 90 stars, based on 1 article reviews
piv-3 sequence accession numbers - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
ImmunoGen Inc pref from rsv, hmpv and piv-3
a – c , Calu-3 mucin GOF cells were infected with ( a ) SARS-CoV-2, ( b ) HKU5-SARS-CoV-S or ( c ) MERS-CoV at an MOI of 0.1. At 24 h postinfection, viral titers were quantified by plaque assay. The dotted line is the NTG average, n = 3 biological replicates. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. d , As a – c , except on WT Calu-3 cells pretreated with StcE. n = 3 biological replicates, two-sided t -tests were performed for the indicated pairs. e , Calu-3 cells were treated with StcE or left untreated and then infected with the indicated virus for 24 h. Relative levels of viral gene copies were quantified by RT–qPCR. Displayed are n = 4 (HCoV-229E), n = 10 (HCoV-OC43), n = 15 (Influenza A virus, PR8), n = 5 <t>(PIV3)</t> and n = 10 (RSV) biological replicates. Two-sided t -tests were performed for the indicated pairs. f , g . Mucin-overexpressing Calu-3 cells were infected with HCoV-229E or PIV3, and relative levels of viral gene copies were quantified 24 h postinfection by RT–qPCR. n = 3 biological replicates, the dotted line is the NTG average. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. h , PIV3 infection of the indicated GOF Calu-3 cells, with and without StcE treatment, at 48 h postinfection quantifying GFP + cells. Displayed is a single time point from the experiment shown in Extended Data Fig. . Displayed are n = 5 biological replicates, two-sided t -tests were performed for the indicated pairs. Dotted lines indicate the NTG average for two separate guides, with (upper) and without (lower) StcE treatment. Error bars denote mean ± s.e.m. NS, not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
Pref From Rsv, Hmpv And Piv 3, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/piv-3/pref+from+rsv++hmpv+and+piv+3/us08889146-819-46-15
Average 90 stars, based on 1 article reviews
pref from rsv, hmpv and piv-3 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Hecin Scientific Inc piv-3
a – c , Calu-3 mucin GOF cells were infected with ( a ) SARS-CoV-2, ( b ) HKU5-SARS-CoV-S or ( c ) MERS-CoV at an MOI of 0.1. At 24 h postinfection, viral titers were quantified by plaque assay. The dotted line is the NTG average, n = 3 biological replicates. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. d , As a – c , except on WT Calu-3 cells pretreated with StcE. n = 3 biological replicates, two-sided t -tests were performed for the indicated pairs. e , Calu-3 cells were treated with StcE or left untreated and then infected with the indicated virus for 24 h. Relative levels of viral gene copies were quantified by RT–qPCR. Displayed are n = 4 (HCoV-229E), n = 10 (HCoV-OC43), n = 15 (Influenza A virus, PR8), n = 5 <t>(PIV3)</t> and n = 10 (RSV) biological replicates. Two-sided t -tests were performed for the indicated pairs. f , g . Mucin-overexpressing Calu-3 cells were infected with HCoV-229E or PIV3, and relative levels of viral gene copies were quantified 24 h postinfection by RT–qPCR. n = 3 biological replicates, the dotted line is the NTG average. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. h , PIV3 infection of the indicated GOF Calu-3 cells, with and without StcE treatment, at 48 h postinfection quantifying GFP + cells. Displayed is a single time point from the experiment shown in Extended Data Fig. . Displayed are n = 5 biological replicates, two-sided t -tests were performed for the indicated pairs. Dotted lines indicate the NTG average for two separate guides, with (upper) and without (lower) StcE treatment. Error bars denote mean ± s.e.m. NS, not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
Piv 3, supplied by Hecin Scientific Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/piv-3/piv+3/pmc11619282-17-20-0
Average 90 stars, based on 1 article reviews
piv-3 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
MedImmune llc recombinant human/bovine piv-3 hpiv-3 bovine n genef
a – c , Calu-3 mucin GOF cells were infected with ( a ) SARS-CoV-2, ( b ) HKU5-SARS-CoV-S or ( c ) MERS-CoV at an MOI of 0.1. At 24 h postinfection, viral titers were quantified by plaque assay. The dotted line is the NTG average, n = 3 biological replicates. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. d , As a – c , except on WT Calu-3 cells pretreated with StcE. n = 3 biological replicates, two-sided t -tests were performed for the indicated pairs. e , Calu-3 cells were treated with StcE or left untreated and then infected with the indicated virus for 24 h. Relative levels of viral gene copies were quantified by RT–qPCR. Displayed are n = 4 (HCoV-229E), n = 10 (HCoV-OC43), n = 15 (Influenza A virus, PR8), n = 5 <t>(PIV3)</t> and n = 10 (RSV) biological replicates. Two-sided t -tests were performed for the indicated pairs. f , g . Mucin-overexpressing Calu-3 cells were infected with HCoV-229E or PIV3, and relative levels of viral gene copies were quantified 24 h postinfection by RT–qPCR. n = 3 biological replicates, the dotted line is the NTG average. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. h , PIV3 infection of the indicated GOF Calu-3 cells, with and without StcE treatment, at 48 h postinfection quantifying GFP + cells. Displayed is a single time point from the experiment shown in Extended Data Fig. . Displayed are n = 5 biological replicates, two-sided t -tests were performed for the indicated pairs. Dotted lines indicate the NTG average for two separate guides, with (upper) and without (lower) StcE treatment. Error bars denote mean ± s.e.m. NS, not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
Recombinant Human/Bovine Piv 3 Hpiv 3 Bovine N Genef, supplied by MedImmune llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/piv-3/recombinant+human+bovine+piv+3+hpiv+3+bovine+n+genef/pm14689350-62-61-50
Average 90 stars, based on 1 article reviews
recombinant human/bovine piv-3 hpiv-3 bovine n genef - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
ModernaTX Inc fusion proteins hmpv piv3
mRNA vaccine candidates for infectious diseases currently in clinical trials
Fusion Proteins Hmpv Piv3, supplied by ModernaTX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/piv-3/fusion+proteins+hmpv+piv3/pmc08940982-131-11-0
Average 90 stars, based on 1 article reviews
fusion proteins hmpv piv3 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Equivalent schedules of intradermal fractional‐dose inactivated poliovirus vaccine compared to intramuscular inactivated poliovirus vaccine for the prevention of poliomyelitis in children

Journal: The Cochrane Database of Systematic Reviews

Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis

doi: 10.1002/14651858.CD011780.pub2

Figure Lengend Snippet: Equivalent schedules of intradermal fractional‐dose inactivated poliovirus vaccine compared to intramuscular inactivated poliovirus vaccine for the prevention of poliomyelitis in children

Article Snippet: The median antibody titre against intramuscular poliovirus type 1 was > 1448 (range = > 1448 to > 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was > 1448 (range = 1176 to > 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group.

Techniques:

Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 1 Seroconversion rate after a single primary dose: type 1 poliovirus.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis

doi: 10.1002/14651858.CD011780.pub2

Figure Lengend Snippet: Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 1 Seroconversion rate after a single primary dose: type 1 poliovirus.

Article Snippet: The median antibody titre against intramuscular poliovirus type 1 was > 1448 (range = > 1448 to > 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was > 1448 (range = 1176 to > 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group.

Techniques:

Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 4 Seroconversion rate after 2 primary doses: type 1 poliovirus.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis

doi: 10.1002/14651858.CD011780.pub2

Figure Lengend Snippet: Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 4 Seroconversion rate after 2 primary doses: type 1 poliovirus.

Article Snippet: The median antibody titre against intramuscular poliovirus type 1 was > 1448 (range = > 1448 to > 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was > 1448 (range = 1176 to > 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group.

Techniques:

Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 7 Seroconversion rate after 3 primary doses: type 1 poliovirus.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis

doi: 10.1002/14651858.CD011780.pub2

Figure Lengend Snippet: Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 7 Seroconversion rate after 3 primary doses: type 1 poliovirus.

Article Snippet: The median antibody titre against intramuscular poliovirus type 1 was > 1448 (range = > 1448 to > 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was > 1448 (range = 1176 to > 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group.

Techniques:

Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 1 Seroconversion rate after a single primary dose: type 1 poliovirus.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis

doi: 10.1002/14651858.CD011780.pub2

Figure Lengend Snippet: Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 1 Seroconversion rate after a single primary dose: type 1 poliovirus.

Article Snippet: The median antibody titre against intramuscular poliovirus type 1 was > 1448 (range = > 1448 to > 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was > 1448 (range = 1176 to > 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group.

Techniques:

Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 4 Seroconversion rate after 2 primary doses: type 1 poliovirus.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis

doi: 10.1002/14651858.CD011780.pub2

Figure Lengend Snippet: Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 4 Seroconversion rate after 2 primary doses: type 1 poliovirus.

Article Snippet: The median antibody titre against intramuscular poliovirus type 1 was > 1448 (range = > 1448 to > 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was > 1448 (range = 1176 to > 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group.

Techniques:

Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 7 Seroconversion rate after 3 primary doses: type 1 poliovirus.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis

doi: 10.1002/14651858.CD011780.pub2

Figure Lengend Snippet: Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 7 Seroconversion rate after 3 primary doses: type 1 poliovirus.

Article Snippet: The median antibody titre against intramuscular poliovirus type 1 was > 1448 (range = > 1448 to > 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was > 1448 (range = 1176 to > 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group.

Techniques:

Geometric titres: children (median titres reported in included studies that could not be used in a meta‐analysis)

Journal: The Cochrane Database of Systematic Reviews

Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis

doi: 10.1002/14651858.CD011780.pub2

Figure Lengend Snippet: Geometric titres: children (median titres reported in included studies that could not be used in a meta‐analysis)

Article Snippet: The median antibody titre against intramuscular poliovirus type 1 was > 1448 (range = > 1448 to > 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was > 1448 (range = 1176 to > 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group.

Techniques: Injection

Comparison 3 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (secondary outcome), Outcome 1 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 1.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis

doi: 10.1002/14651858.CD011780.pub2

Figure Lengend Snippet: Comparison 3 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (secondary outcome), Outcome 1 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 1.

Article Snippet: The median antibody titre against intramuscular poliovirus type 1 was > 1448 (range = > 1448 to > 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was > 1448 (range = 1176 to > 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group.

Techniques:

Comparison 4 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (secondary outcome), Outcome 1 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 1.

Journal: The Cochrane Database of Systematic Reviews

Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis

doi: 10.1002/14651858.CD011780.pub2

Figure Lengend Snippet: Comparison 4 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (secondary outcome), Outcome 1 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 1.

Article Snippet: The median antibody titre against intramuscular poliovirus type 1 was > 1448 (range = > 1448 to > 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was > 1448 (range = 1176 to > 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group.

Techniques:

Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome)

Journal: The Cochrane Database of Systematic Reviews

Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis

doi: 10.1002/14651858.CD011780.pub2

Figure Lengend Snippet: Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome)

Article Snippet: The median antibody titre against intramuscular poliovirus type 1 was > 1448 (range = > 1448 to > 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was > 1448 (range = 1176 to > 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group.

Techniques:

Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome)

Journal: The Cochrane Database of Systematic Reviews

Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis

doi: 10.1002/14651858.CD011780.pub2

Figure Lengend Snippet: Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome)

Article Snippet: The median antibody titre against intramuscular poliovirus type 1 was > 1448 (range = > 1448 to > 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was > 1448 (range = 1176 to > 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group.

Techniques:

Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (secondary outcome)

Journal: The Cochrane Database of Systematic Reviews

Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis

doi: 10.1002/14651858.CD011780.pub2

Figure Lengend Snippet: Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (secondary outcome)

Article Snippet: The median antibody titre against intramuscular poliovirus type 1 was > 1448 (range = > 1448 to > 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was > 1448 (range = 1176 to > 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group.

Techniques:

Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (secondary outcome)

Journal: The Cochrane Database of Systematic Reviews

Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis

doi: 10.1002/14651858.CD011780.pub2

Figure Lengend Snippet: Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (secondary outcome)

Article Snippet: The median antibody titre against intramuscular poliovirus type 1 was > 1448 (range = > 1448 to > 1448) for both GlaxoSmithKline (GSK) and Panacea Biotec groups; type 2 was > 1448 (range = 1176 to > 1448) for both GSK and Panacea Biotec groups; and type 3 was 455 (range = 181 to 910) for the GSK group and 362 (range = 288 to 724) for the Panacea Biotec group.

Techniques:

USDA licensed antiviral and antibacterial vaccines and preventative therapeutic products for cattle.

Journal: Frontiers in Immunology

Article Title: Bovine Immunology: Implications for Dairy Cattle

doi: 10.3389/fimmu.2021.643206

Figure Lengend Snippet: USDA licensed antiviral and antibacterial vaccines and preventative therapeutic products for cattle.

Article Snippet: BHV-1, BVDV, PIV-3, BRSV live vaccine; M. haemolytica bacterin , Boehringer Ingelheim Vetmedica, Elanco US.

Techniques: Vaccines, Virus

Schematic representation of prefusion ( A ) RSV-F (PDB ID: 8W3P) or ( B ) postfusion RSV-F (PDB ID: 3RRT); schematic representation of ( C ) prefusion HMPV-F PDB ID: 7SEJ) or ( D ) postfusion HMPV-F (PDB ID: 7m0i); genome organization of ( E ) HMPV or ( F ) RSV. Created with PyMOL and BioRender.

Journal: Vaccines

Article Title: Vaccine Development for Human Pneumoviruses

doi: 10.3390/vaccines13060569

Figure Lengend Snippet: Schematic representation of prefusion ( A ) RSV-F (PDB ID: 8W3P) or ( B ) postfusion RSV-F (PDB ID: 3RRT); schematic representation of ( C ) prefusion HMPV-F PDB ID: 7SEJ) or ( D ) postfusion HMPV-F (PDB ID: 7m0i); genome organization of ( E ) HMPV or ( F ) RSV. Created with PyMOL and BioRender.

Article Snippet: - RSV/HMPV/PIV3 Sanofi Pasteur , Combined RSV, HMPV, PIV3 mRNA vaccine , Older adults (≥60 yrs.) , Evaluation of safety and immunogenicity— NCT06604767 , - , Recruiting , [ ] .

Techniques:

a – c , Calu-3 mucin GOF cells were infected with ( a ) SARS-CoV-2, ( b ) HKU5-SARS-CoV-S or ( c ) MERS-CoV at an MOI of 0.1. At 24 h postinfection, viral titers were quantified by plaque assay. The dotted line is the NTG average, n = 3 biological replicates. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. d , As a – c , except on WT Calu-3 cells pretreated with StcE. n = 3 biological replicates, two-sided t -tests were performed for the indicated pairs. e , Calu-3 cells were treated with StcE or left untreated and then infected with the indicated virus for 24 h. Relative levels of viral gene copies were quantified by RT–qPCR. Displayed are n = 4 (HCoV-229E), n = 10 (HCoV-OC43), n = 15 (Influenza A virus, PR8), n = 5 (PIV3) and n = 10 (RSV) biological replicates. Two-sided t -tests were performed for the indicated pairs. f , g . Mucin-overexpressing Calu-3 cells were infected with HCoV-229E or PIV3, and relative levels of viral gene copies were quantified 24 h postinfection by RT–qPCR. n = 3 biological replicates, the dotted line is the NTG average. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. h , PIV3 infection of the indicated GOF Calu-3 cells, with and without StcE treatment, at 48 h postinfection quantifying GFP + cells. Displayed is a single time point from the experiment shown in Extended Data Fig. . Displayed are n = 5 biological replicates, two-sided t -tests were performed for the indicated pairs. Dotted lines indicate the NTG average for two separate guides, with (upper) and without (lower) StcE treatment. Error bars denote mean ± s.e.m. NS, not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

Journal: Nature Genetics

Article Title: Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection

doi: 10.1038/s41588-022-01131-x

Figure Lengend Snippet: a – c , Calu-3 mucin GOF cells were infected with ( a ) SARS-CoV-2, ( b ) HKU5-SARS-CoV-S or ( c ) MERS-CoV at an MOI of 0.1. At 24 h postinfection, viral titers were quantified by plaque assay. The dotted line is the NTG average, n = 3 biological replicates. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. d , As a – c , except on WT Calu-3 cells pretreated with StcE. n = 3 biological replicates, two-sided t -tests were performed for the indicated pairs. e , Calu-3 cells were treated with StcE or left untreated and then infected with the indicated virus for 24 h. Relative levels of viral gene copies were quantified by RT–qPCR. Displayed are n = 4 (HCoV-229E), n = 10 (HCoV-OC43), n = 15 (Influenza A virus, PR8), n = 5 (PIV3) and n = 10 (RSV) biological replicates. Two-sided t -tests were performed for the indicated pairs. f , g . Mucin-overexpressing Calu-3 cells were infected with HCoV-229E or PIV3, and relative levels of viral gene copies were quantified 24 h postinfection by RT–qPCR. n = 3 biological replicates, the dotted line is the NTG average. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. h , PIV3 infection of the indicated GOF Calu-3 cells, with and without StcE treatment, at 48 h postinfection quantifying GFP + cells. Displayed is a single time point from the experiment shown in Extended Data Fig. . Displayed are n = 5 biological replicates, two-sided t -tests were performed for the indicated pairs. Dotted lines indicate the NTG average for two separate guides, with (upper) and without (lower) StcE treatment. Error bars denote mean ± s.e.m. NS, not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

Article Snippet: Stocks of PIV3 (PIV3–GFP, ~10 7.4 TCID 50 per ml) and RSV (RSV–GFP1, ~10 7 TCID 50 per ml) were obtained from Viratree.

Techniques: Infection, Plaque Assay, Virus, Quantitative RT-PCR

a . Incucyte trace tracking GFP + (PIV3 infected) cells over 72 hours in Calu-3 mucin GOF cell lines, either pretreated with StcE or not, n = 5 biological replicates. Full dataset for the 48-hour time point from Fig. . b-c . Plaque assay measuring viral loads of the indicated Calu-3 GOF cells infected with HKU5-SARS-Cov-1, or MERS-CoV, respectively, at 24 hpi at an MOI of 0.1. Dotted line indicates the NTG average for guides tested. Significance was calculated by individual two-sided t-tests comparing each cell line to NTG, n = 3 biological replicates. d-e . qRT-PCR measuring viral gene copies 24 hpi in mucin-overexpressing cell lines for 229E (MOI 0.05), or PIV3 (MOI 0.0002), respectively. Dotted line indicates the NTG average. Significance was calculated by individual two-sided t-tests comparing each cell line to NTG, n = 3 biological replicates. f . GFP + (infected) cells from indicated GOF Calu-3 cell lines infected with PIV3 at MOI 0.0002 at 40 hpi. Significance was calculated by individual two-sided t-tests comparing each cell line to NTG, n = 3 biological replicates. Dotted line indicates the NTG average. g . Incucyte trace tracking GFP + infected cells from (f). For all panels : error bars denote mean ± s.e.m., significance is indicated as: n.s.=not significant, *= P < 0.05, **= P < 0.01, ***=P < 0.001, ****= P < 0.0001.

Journal: Nature Genetics

Article Title: Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection

doi: 10.1038/s41588-022-01131-x

Figure Lengend Snippet: a . Incucyte trace tracking GFP + (PIV3 infected) cells over 72 hours in Calu-3 mucin GOF cell lines, either pretreated with StcE or not, n = 5 biological replicates. Full dataset for the 48-hour time point from Fig. . b-c . Plaque assay measuring viral loads of the indicated Calu-3 GOF cells infected with HKU5-SARS-Cov-1, or MERS-CoV, respectively, at 24 hpi at an MOI of 0.1. Dotted line indicates the NTG average for guides tested. Significance was calculated by individual two-sided t-tests comparing each cell line to NTG, n = 3 biological replicates. d-e . qRT-PCR measuring viral gene copies 24 hpi in mucin-overexpressing cell lines for 229E (MOI 0.05), or PIV3 (MOI 0.0002), respectively. Dotted line indicates the NTG average. Significance was calculated by individual two-sided t-tests comparing each cell line to NTG, n = 3 biological replicates. f . GFP + (infected) cells from indicated GOF Calu-3 cell lines infected with PIV3 at MOI 0.0002 at 40 hpi. Significance was calculated by individual two-sided t-tests comparing each cell line to NTG, n = 3 biological replicates. Dotted line indicates the NTG average. g . Incucyte trace tracking GFP + infected cells from (f). For all panels : error bars denote mean ± s.e.m., significance is indicated as: n.s.=not significant, *= P < 0.05, **= P < 0.01, ***=P < 0.001, ****= P < 0.0001.

Article Snippet: Stocks of PIV3 (PIV3–GFP, ~10 7.4 TCID 50 per ml) and RSV (RSV–GFP1, ~10 7 TCID 50 per ml) were obtained from Viratree.

Techniques: Infection, Plaque Assay, Quantitative RT-PCR

mRNA vaccine candidates for infectious diseases currently in clinical trials

Journal: Signal Transduction and Targeted Therapy

Article Title: Advances in COVID-19 mRNA vaccine development

doi: 10.1038/s41392-022-00950-y

Figure Lengend Snippet: mRNA vaccine candidates for infectious diseases currently in clinical trials

Article Snippet: ModernaTX, Inc./mRNA-1653 , hMPV (i.m) , Fusion proteins of hMPV and PIV3 , I , NCT04144348 , Recruiting.

Techniques: